Key terms
About ANAB
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ANAB news
Apr 16
2:56pm ET
AnaptysBio management to meet with Piper Sandler
Apr 16
7:27am ET
AnaptysBio initiated with an Outperform at Leerink
Apr 11
5:35am ET
AnaptysBio initiated with an Overweight at Wells Fargo
Mar 31
10:51am ET
AnaptysBio price target lowered to $28 from $30 at JPMorgan
Mar 18
8:35am ET
5 Stocks that Analysts Love in March 2024
Mar 18
7:45am ET
Truist Financial Reaffirms Their Hold Rating on AnaptysBio (ANAB)
Mar 12
9:02am ET
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), AnaptysBio (ANAB) and REPRO-MED Systems (KRMD)
Mar 12
8:08am ET
Wedbush upgrades AnaptysBio to Outperform into clinical catalysts
Mar 12
6:40am ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), AnaptysBio (ANAB) and iTeos Therapeutics (ITOS)
Mar 12
6:06am ET
AnaptysBio upgraded to Outperform from Neutral at Wedbush
Mar 12
5:47am ET
J.P. Morgan Reaffirms Their Hold Rating on AnaptysBio (ANAB)
Mar 11
7:25pm ET
Strong Buy Rating for AnaptysBio Based on Promising Pipeline and Financial Health
Mar 11
4:19pm ET
AnaptysBio reports Q4 EPS ($1.59), consensus ($1.60)
Feb 26
7:09am ET
AnaptysBio initiated with a Buy at BTIG
Feb 21
9:51am ET
Palo Alto Networks, Home Depot downgraded: Wall Street’s top analyst calls
Feb 20
4:12pm ET
AnaptysBio initiated with a Buy at Stifel
Feb 16
9:37am ET
UPS upgraded, Nike downgraded: Wall Street’s top analyst calls
Feb 16
4:56am ET
AnaptysBio Buy Rating: Strategic Assets and Imminent Milestones Underscore Investment Potential
Feb 16
4:51am ET
AnaptysBio initiated with an Overweight at Piper Sandler
No recent press releases are available for ANAB
ANAB Financials
Key terms
Ad Feedback
ANAB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ANAB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
